Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex Pharmaceuticals (NASDAQ: VRTX) has many promising treatments in its pipeline, as it looks to build out its business beyond just the cystic fibrosis (CF) drugs that have enabled it to post ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Robert A. Hamilton Jr., age 88, passed away at his home in Green Bay on Friday, February 7, 2025. He was born July 1, 1936 in Auburn NY to Robert A. and Ethel I. Hamilton. He graduated from Auburn ...

Having seen the Lewis Hamilton to Ferrari naysayers, Lando Norris said he would have done the same thing in Hamilton’s position. And while there has been plenty of debate over which Lewis ...

F1 “will definitely” be in for another Abu Dhabi title showdown in F1 2025, with Tom Coronel predicting a repeat of 2021 as Lewis Hamilton looks to wrestle back the title from Max Verstappen.

Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years ...

Star safety Kyle Hamilton has been vocal about the team's performance and what they need to improve. In a recent statement on the team's website, Hamilton emphasized that the Ravens have all the ...

FSU football's Caleb Lavalle talks transferring from UNC, excitement for new season FSU football defensive lineman Deante McCray talks about joining the Seminoles FSU defensive lineman Tyeland ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...